Bio‑Rad (BIO) Director Allison Schwartz Receives RSU Shares; Tax Withheld

What Happened

• Allison Schwartz, a director of Bio‑Rad Laboratories (BIO), received 117 shares on September 1, 2026 as the result of restricted stock unit (RSU) vesting (reported as exercise/conversion of a derivative, code M). To satisfy tax withholding obligations, 43 shares were withheld (reported under code F) at a per‑share value of $380.96, totaling $16,381. The filing also reports dispositions of 42 and 75 shares (both M‑coded) in connection with derivative exercises/conversions; each of these conversions shows $0.00 per‑share price in the filing (typical when RSUs convert to shares rather than being purchased).

Key Details

• Transaction date: September 1, 2026; Form 4 filed September 3, 2026 (timely filing).
• Main entries: 117 shares acquired (M); 43 shares withheld/disposed to cover taxes at $380.96/share for $16,381 (F); additional M‑coded dispositions of 42 and 75 shares (reported at $0.00).
• Footnotes: RSUs convert 1:1 to Class A common stock (F1–F2). The reported shares stem from multi‑year RSU grants: 167 RSUs granted 9/1/2022 and 298 RSUs granted 9/1/2023, each vesting in four equal annual installments (F3–F4).
• Shares owned after the transaction are not specified in the provided excerpt.

Context

• These transactions reflect routine RSU vesting and tax withholding rather than an open‑market purchase or sale. The $0.00 exercise price entries reflect conversion of RSUs into shares (not buying shares using cash). Withholding or selling shares to cover taxes is common and doesn’t necessarily indicate a view on the stock.